Ico Therapeutics Company Profile (OTCMKTS:ICOTF)

About Ico Therapeutics

Ico Therapeutics logoiCo Therapeutics Inc. (iCo) is a Canada-based biotechnology company principally focused on the identification, development and commercialization of drug candidates to treat sight-and life-threatening diseases. The Company principally focuses on in-licensing drug candidates with a clinical history, and re-dose, reformulate and develop drug candidates for the treatment of sight-and life-threatening diseases. The Company's product candidates include iCo-007, iCo-008 and an Oral AmpB Delivery System. The Company has initiated Phase II clinical trial for iCo-007. iCo-008 is a human monoclonal antibody that is offered to treat sight threatening forms of allergic conjunctivitis by neutralizing eotaxin-1, a ligand to the chemokine receptor CCR3. Oral AmpB Delivery System is a toxic option for the treatment of serious systemic fungal infections. The Company has completed pre-clinical studies for iCo's Oral AmpB Delivery System.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: OTCMKTS
  • Symbol: ICOTF
  • CUSIP:
Key Metrics:
  • Previous Close: $0.03
  • 50 Day Moving Average: $0.03
  • 200 Day Moving Average: $0.04
  • 52-Week Range: $0.02 - $0.07
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $2.53M
  • Outstanding Shares: 84,457,000
  • Beta: 2.57
Profitability:
  • Return on Equity: -59.51%
  • Return on Assets: -57.48%
Debt:
  • Current Ratio: 18.36%
  • Quick Ratio: 18.36%
Additional Links:
Companies Related to Ico Therapeutics:

Analyst Ratings

Consensus Ratings for Ico Therapeutics (OTCMKTS:ICOTF) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Ico Therapeutics (OTCMKTS:ICOTF)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for Ico Therapeutics (OTCMKTS:ICOTF)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
9/2/2014($0.01)($0.01)ViewN/AView Earnings Details
5/30/2014($0.02)($0.01)ViewN/AView Earnings Details
4/28/2014($0.02)($0.02)ViewN/AView Earnings Details
11/27/2013Q3($0.01)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Ico Therapeutics (OTCMKTS:ICOTF)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Ico Therapeutics (OTCMKTS:ICOTF)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Ico Therapeutics (OTCMKTS:ICOTF)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Ico Therapeutics (OTCMKTS:ICOTF)
DateHeadline
finance.yahoo.com logoiCo Therapeutics Provides Multiple Corporate Updates (OTCMKTS:ICOTF)
finance.yahoo.com - January 23 at 10:56 AM
4-traders.com logoiCo Therapeutics : Announces Positive Study Results and Significant Advances related to Oral Amphotericin B Program (OTCMKTS:ICOTF)
www.4-traders.com - December 14 at 6:31 PM
finance.yahoo.com logoiCo Therapeutics Announces Positive Study Results and Significant Advances Related to Oral Amphotericin B Program (OTCMKTS:ICOTF)
finance.yahoo.com - November 29 at 4:39 PM
finance.yahoo.com logoCLARIFICATION: iCo Therapeutics Announces Positive Study Results and Significant Advances Related to Oral Amphotericin B Program (OTCMKTS:ICOTF)
finance.yahoo.com - November 29 at 4:39 PM
4-traders.com logoIco Therapeutics : posts 3Q loss (OTCMKTS:ICOTF)
www.4-traders.com - November 24 at 8:37 AM
sg.finance.yahoo.com logoIco Therapeutics posts 3Q loss (OTCMKTS:ICOTF)
sg.finance.yahoo.com - November 24 at 8:37 AM
finance.yahoo.com logoiCo Therapeutics Announces Third Quarter 2016 Financial Results (OTCMKTS:ICOTF)
finance.yahoo.com - November 24 at 8:37 AM
finance.yahoo.com logoiCo Therapeutics Announces World Wide Exclusive Option and EU License Rights with Laboratorios SALVAT for Novel Glaucoma Asset (OTCMKTS:ICOTF)
finance.yahoo.com - November 15 at 11:37 AM
publicnow.com logoiCo Therapeutics Announces Voting & Election Results from Annual Meeting of Shareholders (OTCMKTS:ICOTF)
www.publicnow.com - July 12 at 8:33 AM
finance.yahoo.com logoiCo Therapeutics Announces Voting and Election Results from Annual Meeting of Shareholders (OTCMKTS:ICOTF)
finance.yahoo.com - June 27 at 4:46 PM
finance.yahoo.com logoICO THERAPEUTICS INC Financials (OTCMKTS:ICOTF)
finance.yahoo.com - June 8 at 1:04 PM

Social

What is Ico Therapeutics' stock symbol?

Ico Therapeutics trades on the OTCMKTS under the ticker symbol "ICOTF."

How do I buy Ico Therapeutics stock?

Shares of Ico Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Ico Therapeutics stock cost?

One share of Ico Therapeutics stock can currently be purchased for approximately $0.03.

Ico Therapeutics (OTCMKTS:ICOTF) Chart for Tuesday, February, 28, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Ico Therapeutics (OTCMKTS:ICOTF)

Earnings History Chart

Earnings by Quarter for Ico Therapeutics (OTCMKTS:ICOTF)

Dividend History Chart

Dividend Payments by Quarter for Ico Therapeutics (OTCMKTS:ICOTF)

Last Updated on 2/28/2017 by MarketBeat.com Staff